AbbVie Inc. (NYSE:ABBV) was downgraded by investment analysts at Vetr from a “strong-buy” rating to a “buy” rating in a note issued to investors on Monday. They currently have a $67.75 price objective on the stock. Vetr‘s price target would suggest a potential upside of 10.00% from the stock’s current price.

A number of other equities analysts have also weighed in on the stock. Leerink Swann reiterated a “hold” rating on shares of AbbVie in a research report on Tuesday, November 8th. BMO Capital Markets reiterated a “market perform” rating and issued a $63.00 price objective on shares of AbbVie in a research report on Tuesday, November 8th. Citigroup Inc. restated a “buy” rating on shares of AbbVie in a research report on Tuesday, November 8th. Jefferies Group restated a “buy” rating and set a $90.00 target price on shares of AbbVie in a research report on Tuesday, November 1st. Finally, Credit Suisse Group AG lowered shares of AbbVie from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $70.00 to $60.00 in a research report on Monday, October 31st. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have given a buy rating to the company. AbbVie has an average rating of “Hold” and an average price target of $69.54.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Shares of AbbVie (NYSE:ABBV) opened at 61.59 on Monday. The stock has a 50 day moving average of $60.41 and a 200-day moving average of $62.70. The firm has a market capitalization of $100.09 billion, a PE ratio of 16.65 and a beta of 1.55. AbbVie has a 12 month low of $50.71 and a 12 month high of $68.12.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 28th. The company reported $1.21 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.01. AbbVie had a net margin of 24.08% and a return on equity of 150.77%. The firm had revenue of $6.43 billion for the quarter, compared to analyst estimates of $6.55 billion. During the same period last year, the firm posted $1.13 EPS. AbbVie’s quarterly revenue was up 7.4% on a year-over-year basis. On average, equities research analysts anticipate that AbbVie will post $4.82 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 15th. Stockholders of record on Friday, January 13th will be paid a dividend of $0.64 per share. The ex-dividend date of this dividend is Wednesday, January 11th. This represents a $2.56 dividend on an annualized basis and a dividend yield of 4.16%. This is an increase from AbbVie’s previous quarterly dividend of $0.57. AbbVie’s dividend payout ratio is currently 61.62%.

TRADEMARK VIOLATION WARNING: This news story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States & international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2016/11/30/abbvie-inc-abbv-rating-lowered-to-buy-at-vetr-inc.html.

In other news, insider Laura J. Schumacher sold 50,000 shares of the company’s stock in a transaction dated Wednesday, September 7th. The shares were sold at an average price of $65.00, for a total transaction of $3,250,000.00. Following the completion of the transaction, the insider now owns 144,138 shares of the company’s stock, valued at approximately $9,368,970. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.11% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Acropolis Investment Management LLC bought a new position in AbbVie during the second quarter worth approximately $106,000. Penserra Capital Management LLC increased its stake in AbbVie by 100.0% in the third quarter. Penserra Capital Management LLC now owns 1,764 shares of the company’s stock worth $111,000 after buying an additional 882 shares during the period. Glassman Wealth Services increased its stake in AbbVie by 221.1% in the second quarter. Glassman Wealth Services now owns 1,824 shares of the company’s stock worth $113,000 after buying an additional 1,256 shares during the period. Cypress Capital Management LLC WY acquired a new stake in AbbVie during the second quarter worth about $114,000. Finally, Hartford Financial Management Inc. increased its stake in AbbVie by 100.0% in the second quarter. Hartford Financial Management Inc. now owns 1,958 shares of the company’s stock worth $115,000 after buying an additional 979 shares during the period. 66.67% of the stock is owned by institutional investors.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions.

5 Day Chart for NYSE:ABBV

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.